Clinical Trial Detail

NCT ID NCT03377361
Title An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Bristol-Myers Squibb
Indications

colorectal cancer

Therapies

Ipilimumab + Nivolumab

Ipilimumab + Nivolumab + Trametinib

Age Groups: adult senior

Additional content available in CKB BOOST